Literature DB >> 932965

Influence of route of administration on physiological availability of levodopa in dogs.

S Cotler, A Holazo, H G Boxenbaum, S A Kaplan.   

Abstract

The physiological basis for the reduced levodopa bioavailability following oral administration was investigated. Four dogs received single 25-mg/kg doses of 14C-levodopa on three separate occasions in a crossover fashion via hepatoportal catheter, intravenous, and oral administrations. Plasma and urine specimens were analyzed for intact levodopa and total radioactivity. The ratios of areas under the plasma concentration-time curves following hepatoportal and intravenous adminstrations were close to unity, and the shapes of the curves were virtually identical. Following oral administration, however, significant reductions in the areas under the plasma concentration-time curves were observed. These data indicate that the physiologically impaired bioavailability of orally administered levodopa occurs almost exclusively as a result of metabolic degradation within the GI lumen and/or gut wall.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 932965     DOI: 10.1002/jps.2600650607

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study.

Authors:  D Deleu; S Sarre; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

2.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Systemic activity of orally administered L-dopa in the elderly Parkinson patient.

Authors:  M A Evans; E J Triggs; G A Broe; N Saines
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

4.  Lipid synthesis inhibitors: effect on epidermal lipid conformational changes and percutaneous permeation of levodopa.

Authors:  Kumar Babita; Vikas Rana; Ashok K Tiwary
Journal:  AAPS PharmSciTech       Date:  2005-10-24       Impact factor: 3.246

5.  A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.

Authors:  S Grange; N H Holford; T W Guentert
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

6.  Drug metabolism by the gastrointestinal mucosa.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 7.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.